Breaking News Instant updates and real-time market news.

PFE

Pfizer

$33.24

0.085 (0.26%)

, AZN

AstraZeneca

$30.32

0.05 (0.17%)

15:35
07/31/17
07/31
15:35
07/31/17
15:35

On The Fly: What to watch in Pfizer earnings report

Pfizer (PFE) is scheduled to report results of its second quarter before the market open on August 1, with a conference call scheduled for 10:00 am EDT. What to watch for: 1. GUIDANCE: With its first quarter earnings report, Pfizer gave guidance for 2017. The company backed its previous forecast for earnings per share of $2.50-$2.60 on revenue of $52B-$54B. Consensus estimates at the time were for FY17 EPS of $2.55 on revenue of $54.03B. Since then analysts have kept their view on EPS of $2.55 but have ratcheted expectations for FY17 revenue down to $53.1B. Ian Read, chairman and chief executive officer, stated, "I was pleased with our first-quarter 2017 financial performance, which was in line with our expectations, and it reinforces our confidence in the business going forward. I believe each of our businesses is well positioned within their individual markets with strong portfolios, highly skilled and accomplished leadership and focused strategies. Innovative Health's core franchises -- Prevnar 13, Lyrica, Ibrance, Eliquis, Xeljanz and Xtandi -- have strong leadership positions in their respective therapeutic categories and are complemented by new product launches, including Eucrisa and Bavencio, as well as meaningful pipeline progress. Essential Health's growth opportunities -- Sterile Injectables, Biosimilars and Emerging Markets -- continue to perform in line with our expectations while we refine the business and position it for potential sustainable revenue growth. 2. POLITICAL HEADWINDS ABATE: During the month of June, various news outlets reported that President Trump's executive order may be more accommodative to drug companies than feared. The new regime in DC is not looking to have U.S. regulators "negotiate drug prices or allow the importation of cheaper drugs from abroad," said Politico. A meeting in June, which was led by OMB Director Mick Mulvaney and included top leadership of U.S. health agencies, trade officials and senior Trump advisors resulted in little progress on "on even on more modest goals that are said to be an executive order on drug prices," added Politico. MIXED ANALYST VIEWS: In late June, Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm said the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). However, Credit Suisse analyst Vamil Divan in a recent note, downgraded Pfizer to Neutral and lowered his price target for the shares to $36 from $38. The analyst, who noted that he's long been a supporter of Pfizer and continues to see opportunities for upside over the long-term, said he believes the stock's upside drivers are more limited over the next year. Divan prefers other names in the Major Pharmaceuticals space, such as Johnson & Johnson (JNJ) and Merck (MRK). Growth of Pfizer's Ibrance is slowing while global Prevnar sales are flat to declining, Divan tells investors in a research note. He adds that the company is facing two meaningful patent expirations over the next 18 months with Viagra and Lyrica.

PFE

Pfizer

$33.24

0.085 (0.26%)

AZN

AstraZeneca

$30.32

0.05 (0.17%)

BMY

Bristol-Myers

$56.92

1.65 (2.99%)

LLY

Eli Lilly

$82.85

-0.255 (-0.31%)

GSK

GlaxoSmithKline

$40.51

-0.42 (-1.03%)

JNJ

Johnson & Johnson

$132.88

1.03 (0.78%)

MRK

Merck

$63.86

-0.25 (-0.39%)

NVS

Novartis

$85.20

0.45 (0.53%)

SNY

Sanofi

$47.50

-0.06 (-0.13%)

  • 31

    Jul

  • 01

    Aug

  • 02

    Aug

  • 03

    Aug

  • 09

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 11

    Sep

  • 22

    Sep

  • 22

    Sep

  • 24

    Sep

  • 24

    Oct

  • 09

    Nov

  • 05

    Mar

  • 17

    May

PFE Pfizer
$33.24

0.085 (0.26%)

07/20/17
07/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan saying he believes the stock's upside drivers are more limited over the next year. 2. Rite Aid (RAD) downgraded to Neutral from Buy at Mizuho. 3. Fairmount Santrol (FMSA) was downgraded to Sell from Neutral at Goldman Sachs and to Neutral from Outperform at Credit Suisse. 4. New Relic (NEWR) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Sanjit Singh saying shares are up 71% year-to-date and valuation captures solid fundamentals but sees fewer catalysts. 5. Smart Sand (SND) downgraded to Neutral from Outperform at Credit Suisse with analyst James Wicklund saying the regional sand volumes capacity is expanding much faster than had been expected. This drives lower pricing and demand for non-Texas mines, he adds. The analyst also lowered his price target on the shares to $8.50 from $20. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/20/17
FBCO
07/20/17
DOWNGRADE
Target $36
FBCO
Neutral
Pfizer downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Vamil Divan downgraded Pfizer to Neutral and lowered his price target for the shares to $36 from $38. The shares closed yesterday up 26c to $33.62. The analyst, who notes he's long been a supporter of Pfizer and continues to see opportunities for upside over the long-term, believes the stock's upside drivers are more limited over the next year. Divan prefers other names in the Major Pharmaceuticals space, such as Johnson & Johnson (JNJ) and Merck (MRK). Growth of Pfizer's Ibrance is slowing while global Prevnar sales are flat to declining, Divan tells investors in a research note. He adds that the company is facing two meaningful patent expirations over the next 18 months with Viagra, Lyrica.
07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
06/29/17
JEFF
06/29/17
UPGRADE
Target $117
JEFF
Buy
Icon upgraded to Buy from Hold at Jefferies
Jefferies analyst David Windley upgraded Icon (ICLR) to Buy saying the shares continue to trade at a group discount. The analyst sees "solid appreciation potential" as Pfizer (PFE) concentration is reduced and potentially 45% upside with a more aggressive acquisition strategy. The company's management has talked more openly about larger deals, Windley tells investors in a research note. Windley raised his price target for Icon shares to $117 from $86.
AZN AstraZeneca
$30.32

0.05 (0.17%)

07/28/17
07/28/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Starbucks (SBUX) was downgraded to Neutral from Buy at Guggenheim and to Hold from Buy at Stifel. 2. Spirit Airlines (SAVE) was downgraded to Neutral from Buy at Buckingham and BofA/Merrill and to In-Line from Outperform at Imperial Capital. 3. Flowers Foods (FLO) downgraded to Hold from Buy at Jefferies with analyst Akshay Jagdale saying his positive thesis on bread industry pricing becoming more rational has not played out. 4. AstraZeneca (AZN) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Vincent Meunier saying shares look fairly valued as he removed MYSTIC from his models. 5. U.S. Steel (X) downgraded to Sell from Neutral at Citi with analyst Alexander Hacking saying he sees downside risk to U.S. flat rolled prices for the remainder of 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/28/17
MSCO
07/28/17
DOWNGRADE
MSCO
Equal Weight
AstraZeneca downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Vincent Meunier downgraded AstraZeneca to Equal Weight saying shares look fairly valued as he removed MYSTIC from his models. The analyst said AstraZeneca has lower margin recovery prospects and reduced optionality from the pipeline near-term.
07/28/17
RHCO
07/28/17
NO CHANGE
RHCO
Merck, AstraZeneca deal positive, says SunTrust
After Merck (MRK) paid $1.6B upfront for access to Astrazeneca's (AZN) PARP inhibitor, Lynparza and another drug, SunTrust analyst John Boris says that the deal "makes strategic/financial sense and validates the PARP inhibitor class." He adds that the companies are "ideally positioned" to leverage a combination of IO and PARP therapies. The analyst reiterates a $73 price target and a Buy rating on Merck.
07/28/17
LEER
07/28/17
NO CHANGE
Target $61
LEER
Outperform
Bristol-Myers price target lowered to $61 after Astra trial setback at Leerink
Leerink analyst Seamus Fernandez said Bristol-Myers (BMY) reported "solid" Q2 results, including encouraging growth for its key franchises, but he sees increased uncertainty following the failure of AstraZeneca's (AZN) MYSTIC trial, which has potential read through to Bristol's CheckMate-227 trial of its I/O combo of Opdivo + Yervoy. Fernandez lowered his price target on Bristol shares to $61 from $66, but "fully acknowledges" the range of differences in the trial designs. He keeps an Outperform rating on Bristol-Myers, citing prospects for monotherapy Opdivo approval in the second-line setting and success in first-line liver cancer.
BMY Bristol-Myers
$56.92

1.65 (2.99%)

07/31/17
LEER
07/31/17
NO CHANGE
LEER
Outperform
Clovis weakness unwarranted after Bristol-Myers pact, says Leerink
Leerink analyst Michael Schmidt thinks today's weakness in Clovis (CLVS) is unwarranted following the company's clinical collaboration agreement with Bristol-Myers (BMY) and presents a buying opportunity. This deal does not preclude a future acquisition of the company, but it does increase the competitiveness and value of Rubraca, argues Schmidt, who reiterates his Outperform rating on Clovis shares.
07/31/17
JANY
07/31/17
NO CHANGE
Target $107
JANY
Buy
Clovis partnership undercuts takeover thesis, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay says Clovis Oncology's (CLVS) clinical partnership with Bristol-Myer Squibb (BMY) undercuts his takeout thesis. The recent agreements across the PARP drugs implies no near-term takeovers, Chattopadhyay tells investors in a research note. He believes this will "likely to be disappointing to many." The analyst has a Buy rating on Clovis with a $107 price target. The shares in early trading are down $8.04, or 8% to $89.97.
07/27/17
LEER
07/27/17
NO CHANGE
LEER
Outperform
AstraZeneca trial failure negative for Bristol-Myers, says Leerink
Leerink analyst Seamus Fernandez notes that AstraZeneca (AZN) announced that the MYSTIC trial failed to show a progression-free survival benefit for Imfinzi + tremelimumab compared to chemotherapy in first-line non-small cell lung cancer patients with PDL1 expression greater than 25%. The read through is an obvious negative readthrough for Bristol-Myers' (BMY) combo of Opdivo + Yervoy in the ongoing CheckMate-227 trial, the analyst says. He points out that while there are several key differences in trial design between MYSTIC and CM-227, they are unlikely to result in meaningfully different outcomes. Fernandez reiterates an Outperform rating on Bristol-Myers' shares.
LLY Eli Lilly
$82.85

-0.255 (-0.31%)

07/26/17
LEER
07/26/17
DOWNGRADE
LEER
Market Perform
Eli Lilly downgraded to Market Perform from Outperform at Leerink
07/26/17
07/26/17
DOWNGRADE
Target $90

Market Perform
Eli Lilly downgraded to Market Perform at Leerink
As previously reported, Leerink analyst Seamus Fernandez downgraded Eli Lilly to Market Perform from Outperform, citing intense competition and saying that the regulatory update for Olumiant removes upside optionality in rheumatoid arthritis and possibly other indications given concerns over thrombosis risk. The analyst also lowered his price target on the shares to $90 from $93.
07/26/17
07/26/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AMD (AMD) downgraded to Market Perform from Outperform at BMO Capital. 2. Zoetis (ZTS) downgraded to Hold from Buy at Deutsche Bank with analyst Gregg Gilbert saying the risk/reward is more balanced with the shares up 18% year-to-date. 3. CF Industries (CF) downgraded to Neutral from Outperform at Credit Suisse with analyst Christopher Parkinson citing the recent rally in shares. 4. Eli Lilly (LLY) downgraded to Market Perform from Outperform at Leerink with analyst Seamus Fernandez saying that the regulatory update for Olumiant removes upside optionality in rheumatoid arthritis and possibly other indications given concerns over thrombosis risk. 5. Wynn Resorts (WYNN) was downgraded to Hold from Buy at Union Gaming and to Market Perform from Outperform at Telsey Advisory. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/25/17
COWN
07/25/17
NO CHANGE
Target $95
COWN
Outperform
Eli Lilly delay for baricitinib 'a cloud' over Q2 report, says Cowen
Cowen analyst Steve Scala said that Eli Lilly's Q2 revenue and EPS beat was driven by "solid sales" across most of its key products and he raised his 2017 estimate by a nickel to $4.15 after the company raised its own forecasts for 2017 earnings and sales. However, he called the delay in the resubmission of the NDA for baricitinib for RA a "disappointment" and "a cloud" amid the earnings report. Scala has an Outperform rating and $95 price target on Lilly shares.
GSK GlaxoSmithKline
$40.51

-0.42 (-1.03%)

07/05/17
SBSH
07/05/17
DOWNGRADE
SBSH
Neutral
GlaxoSmithKline downgraded to Neutral from Buy at Citi
Citi analyst Andrew Baum downgraded GlaxoSmithKline (GSK) to Neutral and lowered his price target for the shares to GBP 17 from GBP 18. The analyst believes the market is underappreciating the slowing of the company's HIV market growth. He prefers shares of AstraZeneca (AZN), Roche (RHHBY) and Bayer (BAYRY) for exposure to Europe.
06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/05/17
07/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Capital One (COF) downgraded to Underperform from Neutral at Wedbush with analyst Henry Coffey saying ROE from operations is much lower than expected, and return on capital measures are sub-optimal. 2. Weyerhaeuser (WY) downgraded to Neutral from Buy at BofA/Merrill with analyst George Staphos saying his thesis has played out and catalysts are limited in the intermediate term. 3. Buffalo Wild Wings (BWLD) downgraded to Equal Weight from Overweight at Stephens with analyst Will Slabaugh saying the proxy fight and management shake-up has created uncertainty regarding the company's future and said a downward revision to guidance is likely due to continued margin pressures, soft topline trends, and lack of near-term catalysts. 4. GlaxoSmithKline (GSK) downgraded to Neutral from Buy at Citi with analyst Andrew Baum saying he believes the market is under-appreciating the slowing of the company's HIV market growth. 5. Oneok (OKE) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Tom Abrams saying risk/reward is balanced. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/10/17
PIPR
07/10/17
NO CHANGE
Target $5
PIPR
Neutral
OncoMed termination from GSK not surprising, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes GlaxoSmithKline (GSK) terminating its agreement with OncoMed Pharmaceuticals (OMED) is not surprising since tarextumab, the only remaining asset under the collaboration, failed previously to meet the primary endpoint in a Phase II study for first-line small cell lung cancer. The analyst says he remains focused on OncoMed's early stage pipeline including navicixizumab, rosmantuzumab and I/O assets anti-TIGIT and GITR trimer. Tenthoff keeps a Neutral rating on OncoMed with a $5 price target.
JNJ Johnson & Johnson
$132.88

1.03 (0.78%)

07/21/17
ATLE
07/21/17
DOWNGRADE
Target $113
ATLE
Underweight
Johnson & Johnson downgraded to Underweight from Neutral at Atlantic Equities
Atlantic Equities analyst Steve Chesney downgraded Johnson & Johnson to Underweight while raising his price target for the shares to $113 from $112.
07/21/17
ATLE
07/21/17
DOWNGRADE
Target $113
ATLE
Underweight
J&J downgraded to Underweight on 'growth headwinds' at Atlantic Equities
Atlantic Equities analyst Steve Chesney downgraded Johnson & Johnson to Underweight from Neutral saying the Q2 results "highlight underlying growth headwinds." The analyst also sees more challenging comps into FY18. On the pipeline, Chesney thinks expectations are already high for near-term catalysts including the COMPASS data. The analyst raised his price target for the shares to $113 from $112. J&J closed yesterday up $1.36 to $136.57. BTIG this morning also downgraded the shares to Sell.
07/21/17
07/21/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) was downgraded to Sell from Neutral at BTIG and to Underweight from Neutral at Atlantic Equities. 2. Wells Fargo (WFC) downgraded to Sell from Hold at Berenberg with analyst James Chappell saying the bank's competitive advantages have been eroded. 3. RH (RH) downgraded to Hold from Buy at Deutsche Bank with analyst Adam Sindler citing valuation with the stock up 36% over the past month and 15% this week alone. 4. Union Pacific (UNP) downgraded to Hold from Buy at Deutsche Bank with analyst Amit Mehrotra saying moderating volumes as well as risks to industrial production in the second half of the year and beyond will limit share upside over the medium term. 5. Check Point (CHKP) downgraded to Neutral from Overweight at Piper Jaffray with analyst Andrew Nowinski saying with the stock up 27% year-to-date, the valuation has now "reached a peak" given the decelerating billings, product/subscription and free cash flow growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/21/17
BTIG
07/21/17
DOWNGRADE
Target $110
BTIG
Sell
Johnson & Johnson downgraded to Sell from Neutral at BTIG
BTIG analyst Dane Leone downgraded Johnson & Johnson to Sell from Neutral as he expects the company's Pharmaceuticals segment to see "lackluster" sales growth through 2021 and he remains skeptical of the long-term value from the Actelion acquisition. Leone has a $110 price target on J&J shares.
MRK Merck
$63.86

-0.25 (-0.39%)

07/27/17
FBCO
07/27/17
NO CHANGE
FBCO
Merck unlikely to buy PARP company after Astra deal, says Credit Suisse
Credit Suisse analyst Alethia Young believes Merck (MRK) is unlikely to acquire a PARP inhibitor company like Tesaro (TSRO) or Clovis (CLVS) after inking an immuno-oncology deal with AstraZeneca (AZN).
07/27/17
GSCO
07/27/17
NO CHANGE
GSCO
Merck could trade up $5 following AstraZeneca MYSTIC failure, says Goldman Sachs
Goldman analyst Jami Rubin expects Merck (MRK) to trade up approximately $5 based on sentiment following AstraZeneca's MYSTIC failure as it partially de-risks longer-term estimates for Keytruda. As a result, the analyst raised Merck's Keytruda sales estimates by $600M in 2018 and $1B in 2019 and beyond, increasing earnings estimates by 14c-20c, and raising his price target on shares to $74 from $70. Rubin cautions that long-term estimates could be at risk if other competitor trials are successful. The analyst rates Merck a Neutral.
07/27/17
JANY
07/27/17
NO CHANGE
Target $107
JANY
Buy
PARP deals may make Clovis more attractive buyout candidate, says Janney
The partnerships announced today between AstraZeneca (AZN) and Merck (MRK) as well as Tesaro (TSRO) and Takeda highlight pharma's willingness to expand on PARP's, Janney analyst Debjit Chattopadhyay tells investors in a research note. Clovis' (CLVS) Rubraca is now the only unencumbered PARP and is "far cheaper" on a relative valuation basis than peer Tesaro, the analyst adds. He believes Clovis could now become a more compelling takeover candidate. Chattopadhyay has a Buy rating on the shares with a $107 price target. The stock in midday trading is up 7%, or $5.90, to $93.33.
NVS Novartis
$85.20

0.45 (0.53%)

07/26/17
JANY
07/26/17
NO CHANGE
Target $8
JANY
Buy
Cryoport 2018 visibility 'locked down' with Novartis pact, says Janney Capital
Janney Capital analyst Paul Knight estimates Cryoport's (CYRX) three year deal to provide Novartis (NVS) shipping and logistics services for CTL019 will yield $8M-$10M of annual revenue, which "locks down" the company's 2018 visibility. He keeps a Buy rating and $8 fair value estimate on Cryoport shares.
07/26/17
07/26/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Chipotle (CMG) upgraded to Hold from Underperform at Jefferies with analyst Andy Barish saying the current valuation and consensus estimates "now reflect the reality" of Chipotle's path to recovery. 2. Biogen (BIIB) upgraded to Buy from Neutral at Goldman Sachs with analyst Terence Flynn saying the company's balance sheet is under-levered, which provides flexibility, while Aducanumab provides Alzheimer's optionality. 3. DSW (DSW) upgraded to Outperform from Neutral at Wedbush with the firm saying it is more confident that second quarter results will beat expectations and that the company will reiterate its full-year guidance after conducting checks and speaking with the company. 4. Electronic Arts (EA) upgraded to Buy from Neutral at BofA/Merrill with analyst Justin Post citing a strong fiscal 2019 outlook. 5. Novartis (NVS) upgraded to Overweight from Underweight at Morgan Stanley with analyst Vincent Meunier upgrading the company two notches to Overweight from Underweight following a "massive" reset in consensus expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/26/17
MSCO
07/26/17
UPGRADE
MSCO
Overweight
Novartis upgraded to Overweight from Underweight at Morgan Stanley
Morgan Stanley analyst Vincent Meunier upgraded Novartis two notches to Overweight from Underweight following a "massive" reset in consensus expectations. The analyst said a turnaround of Alcon is underway and 2017 Entresto expectations have been cut in half since early 2016 and appear achievable. Meunier said recent quarterly news flow implies a less risky outlook and valuation provides an improved risk/reward.
07/21/17
WELS
07/21/17
NO CHANGE
WELS
Outperform
Amphastar 'David-vs-Goliath' win over Momenta a major victory, says Wells Fargo
Wells Fargo analyst David Maris said a jury's ruling that a Momenta (MNTA) patent was invalid and unenforceable is a very positive outcome for Amphastar (AMPH) in its "David-vs-Goliath-type" case. While he expects Momenta and partner Novartis' (NVS) Sandoz to appeal, Maris thinks this ruling puts Amphastar in a good position for any future potential settlement talks. Maris does not think investors should "count on any windfall" for Amphastar, but he does think, if approved, this could be an over $50M opportunity and keeps an Outperform rating on the stock, which is up 2% to $18.32 in afternoon trading.
SNY Sanofi
$47.50

-0.06 (-0.13%)

07/10/17
PIPR
07/10/17
NO CHANGE
Target $126
PIPR
Overweight
Alnylam shares overreacting to ALT elevations in OLE data, says Piper Jaffray
Alnylam (ALNY) and partner Sanofi (SNY) presented new Phase II open-label extension study data on 33 hemophilia patients being treated with fitusiran and reported that eleven patients reported asymptomatic ALT increases, up from three observed in its ASH meeting update, noted Piper Jaffray analyst Edward Tenthoff. However, he thinks the stock is overreacting, as the liver enzyme elevations were asymptomatic and largely reversed within one month, he tells investors. Tenthoff, who also sees the efficacy data as encouraging, reiterates his Overweight rating and $126 price target on Alnylam shares.
07/14/17
WELS
07/14/17
NO CHANGE
Target $41
WELS
Outperform
Wells says smallpox vaccine deal an 'excellent fit' for Emergent BioSolutions
Wells Fargo analyst David Maris said Emergent BioSolutions' (EBS) deal to acquire the ACAM2000 smallpox vaccine business of Sanofi (SNY) is "an excellent fit" and he is "encouraged" by its ability to identify and make a deal for such a "solid target." Maris keeps an Outperform rating and $41 price target on Emergent BioSolutions.
07/31/17
PIPR
07/31/17
NO CHANGE
Target $557
PIPR
Overweight
Regeneron indicated lower after Sanofi earnings report, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says shares of Regeneron (REGN) are indicated lower after partner Sanofi (SNY) reported Q2 U.S. Dupixent sales of $30M in adults with atopic dermatitis. This was essentially in line with the consensus estimate of $33M, Tenthoff tells investors in a research note. He adds that over 5,100 physicians have prescribed and over 13,000 atopic dermatitis patients have been prescribed Dupixent as of July 26. The analyst views the launch stats as impressive and reiterates an Overweight rating on Regeneron with a $557 price target.
07/31/17
ADAM
07/31/17
NO CHANGE
Target $522
ADAM
Buy
Dupixent authorization approval rate outweighs Q2 miss, says Canaccord
Regeneron (REGN) partner Sanofi (SNY) reported a "very high" 73%-83% prior authorization approval rate for Dupixent in Q2, which Canaccord analyst John Newman said outweighs the fact that sales for the drug at $30.6M were slightly below the $33M consensus forecast. The analyst, who sees rapid payor acceptance of Dupixent as "much more crucial" than the initial quarterly revenue, keeps a Buy rating and $522 price target on Regeneron shares.

TODAY'S FREE FLY STORIES

JPM

JPMorgan

$90.56

-0.18 (-0.20%)

, AAPL

Apple

$157.50

-0.36 (-0.23%)

11:43
08/21/17
08/21
11:43
08/21/17
11:43
Periodicals
JPMorgan pledges up to $2M to anti-hate groups, CNBC reports »

JPMorgan (JPM) is…

JPM

JPMorgan

$90.56

-0.18 (-0.20%)

AAPL

Apple

$157.50

-0.36 (-0.23%)

FOX

21st Century Fox

$26.79

-0.1 (-0.37%)

FOXA

21st Century Fox

$27.26

-0.09 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 07

    Sep

  • 11

    Sep

  • 12

    Oct

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

SNA

Snap-On

$142.41

-5.55 (-3.75%)

11:41
08/21/17
08/21
11:41
08/21/17
11:41
Technical Analysis
Technical View: Snap-On falls to session lows, analyst action »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 06

    Sep

TV

Grupo Televisa

$25.75

0.31 (1.22%)

11:40
08/21/17
08/21
11:40
08/21/17
11:40
Options
Put seller opens a large position in Grupo Televisa »

Put seller opens a large…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:40
08/21/17
08/21
11:40
08/21/17
11:40
General news
Fed's inaugural SCE Labor Market Survey surprisingly dour: »

Fed's inaugural SCE…

CYH

Community Health

$7.63

0.595 (8.46%)

11:37
08/21/17
08/21
11:37
08/21/17
11:37
Hot Stocks
ASL Strategic Value Fund calls on Community Health board to replace CEO »

ASL Strategic Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 06

    Sep

11:37
08/21/17
08/21
11:37
08/21/17
11:37
Hot Stocks
Breaking Hot Stocks news story  »

Stellus Capital…

BRK.A

Berkshire Hathaway

$267,800.00

423 (0.16%)

, BRK.B

Berkshire Hathaway

$177.86

0.3 (0.17%)

11:36
08/21/17
08/21
11:36
08/21/17
11:36
Hot Stocks
Berkshire Hathaway Energy agreement to acquire Oncor terminated by EFH »

Berkshire Hathaway Energy…

BRK.A

Berkshire Hathaway

$267,800.00

423 (0.16%)

BRK.B

Berkshire Hathaway

$177.86

0.3 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$10.62

0.06 (0.57%)

, AAPL

Apple

$157.50

-0.36 (-0.23%)

11:36
08/21/17
08/21
11:36
08/21/17
11:36
Periodicals
Ford CTO: Autonomous vehicles need more than just software, Axios reports »

Ford (F) CTO Ken…

F

Ford

$10.62

0.06 (0.57%)

AAPL

Apple

$157.50

-0.36 (-0.23%)

GOOG

Alphabet

$910.67

-0.31 (-0.03%)

GOOGL

Alphabet Class A

$926.18

-1.48 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 24

    Aug

PNW

Pinnacle West

$89.26

-0.03 (-0.03%)

11:35
08/21/17
08/21
11:35
08/21/17
11:35
Hot Stocks
Pinnacle West says Commissioner Burns files petition to vacate ACC's order »

On August 18, the ACC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:34
08/21/17
08/21
11:34
08/21/17
11:34
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

11:34
08/21/17
08/21
11:34
08/21/17
11:34
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

MCD

McDonald's

$158.46

0.7 (0.44%)

11:31
08/21/17
08/21
11:31
08/21/17
11:31
Periodicals
McDonald's to close 169 outlets in northern, eastern India, Reuters reports »

McDonald's is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

AEO

American Eagle

$10.40

-0.715 (-6.44%)

11:30
08/21/17
08/21
11:30
08/21/17
11:30
Options
American Eagle puts active as shares touch 52-week lows »

American Eagle puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

PNW

Pinnacle West

$89.00

-0.2899 (-0.32%)

11:29
08/21/17
08/21
11:29
08/21/17
11:29
Earnings
Breaking Earnings news story on Pinnacle West »

Pinnacle West sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYR

DJ US Real Estate Index Fund

$79.79

0.61 (0.77%)

, XLV

Health Care Select Sector SPDR

$78.27

0.27 (0.35%)

11:25
08/21/17
08/21
11:25
08/21/17
11:25
Technical Analysis
S&P 500 trades near top of range for the day as mid-session approaches »

The S&P 500 (SPX) is…

IYR

DJ US Real Estate Index Fund

$79.79

0.61 (0.77%)

XLV

Health Care Select Sector SPDR

$78.27

0.27 (0.35%)

XLP

Consumer Staples Sector SPDR

$55.35

0.145 (0.26%)

XLB

S&P Select Materials SPDR

$53.82

0.105 (0.20%)

XLU

Utilities SPDR

$54.56

0.06 (0.11%)

XLE

Energy Select Sector SPDR

$62.05

-0.27 (-0.43%)

XLF

Financial Select Sector

$24.49

-0.13 (-0.53%)

XLK

Technology Select Sector SPDR

$56.83

-0.245 (-0.43%)

SPY

SPDR S&P 500 ETF Trust

$242.46

-0.25 (-0.10%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXDX

Accelerate Diagnostics

$21.70

-1.85 (-7.86%)

11:22
08/21/17
08/21
11:22
08/21/17
11:22
Recommendations
Accelerate Diagnostics analyst commentary  »

Piper sees several…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETE

Energy Transfer Equity

$16.54

-0.135 (-0.81%)

11:20
08/21/17
08/21
11:20
08/21/17
11:20
Options
Short-term call buyer in Energy Transfer Equity »

Short-term call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
08/21/17
08/21
11:17
08/21/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
08/21/17
08/21
11:16
08/21/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
08/21/17
08/21
11:15
08/21/17
11:15
General news
Treasury announced a $30 B 4-week bill sale for Tuesday »

Treasury announced a $30…

11:15
08/21/17
08/21
11:15
08/21/17
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

11:15
08/21/17
08/21
11:15
08/21/17
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

PAYX

Paychex

$54.99

0.01 (0.02%)

11:11
08/21/17
08/21
11:11
08/21/17
11:11
Hot Stocks
Paychex acquires HR Outsourcing Holdings; terms not disclosed »

Paychex announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 30

    Oct

AXDX

Accelerate Diagnostics

$21.70

-1.85 (-7.86%)

11:10
08/21/17
08/21
11:10
08/21/17
11:10
Hot Stocks
Accelerate Diagnostics CEO trades 223K shares for shares of exchange fund »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FEYE

FireEye

$13.98

-0.01 (-0.07%)

11:10
08/21/17
08/21
11:10
08/21/17
11:10
Options
Vote of confidence in FireEye »

Vote of confidence in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 11

    Sep

  • 19

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.